Jaguar Health, Inc. is a specialty pharmaceutical company focused on developing and commercializing sustainably derived, plant-based prescription drugs for gastrointestinal disorders in humans and animals. Operating primarily through its wholly owned subsidiary Napo Pharmaceuticals, Inc., the company targets unmet medical needs in complex gastrointestinal disease states, including rare and orphan conditions. Jaguar Health also collaborates with Filament Health Corp. through…
Jaguar Health, Inc. is a specialty pharmaceutical company focused on developing and commercializing sustainably derived, plant-based prescription drugs for gastrointestinal disorders in humans and animals. Operating primarily through its wholly owned subsidiary Napo Pharmaceuticals, Inc., the company targets unmet medical needs in complex gastrointestinal disease states, including rare and orphan conditions. Jaguar Health also collaborates with Filament Health Corp. through the joint venture Magdalena Biosciences to explore plant-based therapies for mental health indications, such as adult attention-deficit/hyperactivity disorder. The company’s pipeline centers on crofelemer, a novel anti-secretory agent extracted from the Croton lechleri tree, which normalizes electrolyte and fluid balance in the gastrointestinal tract.
The company generates revenue primarily through the sale of its FDA-approved prescription products and licensing agreements. Its flagship product, Mytesi (crofelemer 125 mg delayed-release tablets), is approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In January 2026, Jaguar licensed U. S. commercialization rights for Mytesi and Canalevia-CA1, its chemotherapy-induced diarrhea treatment for dogs, to Future Pak, LLC, securing $16 million in non-dilutive capital and potential milestone payments of up to $20 million. Additionally, Jaguar launched Gelclair, an oral mucositis prescription gel, in the U. S. market in October 2024. The company also earns revenue from manufacturing crofelemer for its licensees and through international distribution agreements, such as those with Quadri Pharmaceuticals Store LLC in the Middle East and Knight Therapeutics Inc. in Canada and Israel.
The company operates through the following segments:
• Human Health: This segment focuses on the development and commercialization of crofelemer-based therapies for gastrointestinal disorders in humans. Key programs include Mytesi for HIV-related diarrhea, crofelemer powder for oral solution for rare pediatric and adult intestinal failure conditions such as microvillus inclusion disease and short bowel syndrome, and NP-300, a second-generation anti-secretory drug for infectious diarrhea, including cholera. The segment also encompasses the commercialization of Gelclair for oral mucositis in cancer patients.
• Animal Health: This segment develops and markets gastrointestinal therapies for companion animals, primarily dogs. Its lead product, Canalevia-CA1 (crofelemer delayed-release tablets), is conditionally approved by the FDA for the treatment of chemotherapy-induced diarrhea in dogs. The segment operates under the Jaguar Animal Health tradename and continues to explore additional indications for crofelemer in veterinary medicine.
• Mental Health (Magdalena Biosciences): This segment, a joint venture with Filament Health Corp., focuses on developing novel, plant-based prescription medicines for mental health disorders. The initial target is adult attention-deficit/hyperactivity disorder, leveraging Jaguar’s proprietary library of medicinal plants and Filament’s drug development technology.
Jaguar Health occupies a distinctive position in the gastrointestinal pharmaceutical industry, targeting niche and underserved markets with first-in-class, plant-derived therapies. Its primary competitive advantage lies in crofelemer’s unique mechanism of action, which modulates intestinal chloride ion secretion to normalize fluid and electrolyte balance, addressing conditions where existing treatments are limited or nonexistent. In the rare disease space, crofelemer powder for oral solution is positioned as a paradigm-shifting therapy for microvillus inclusion disease and short bowel syndrome, conditions currently managed with lifelong parenteral support. Competitors in this segment include Takeda Pharmaceuticals, which markets GATTEX (teduglutide) for short bowel syndrome, though crofelemer’s earlier administration post-surgery and broader patient eligibility provide a differentiating edge. For infectious diarrhea, NP-300 aims to fill a gap where no FDA-approved anti-secretory drugs exist, competing with standard oral rehydration salts and antibiotics. The company’s intellectual property portfolio, comprising approximately 195 patents with expirations extending to 2031, further strengthens its market position by securing exclusivity for its innovations.
The company serves a diverse customer base across its segments. In human health, its primary customers include adults with HIV/AIDS experiencing noninfectious diarrhea, cancer patients undergoing chemotherapy or targeted therapies, and individuals with rare gastrointestinal disorders such as microvillus inclusion disease and short bowel syndrome. Gelclair targets cancer patients suffering from oral mucositis. In animal health, the customer base consists of veterinarians and pet owners, particularly those managing dogs with chemotherapy-induced diarrhea. While specific customer names are not disclosed, Jaguar’s products are distributed through partnerships with specialty pharmaceutical companies, including Future Pak in the U. S. and Knight Therapeutics in Canada and Israel. The company also engages with healthcare providers, hospitals, and clinics globally, particularly in regions with high unmet medical needs.
Sector:HealthcareSector rationaleJaguar Health is a specialty pharmaceutical company that develops and commercializes prescription drugs, such as Mytesi and Gelclair, for human and animal gastrointestinal disorders. Its revenue is derived from the sale of FDA-approved medical products, licensing agreements for drug commercialization, and manufacturing pharmaceutical agents.Industries:PharmaceuticalsHealthcarePrimaryJaguar Health is a specialty pharmaceutical company that develops and markets branded prescription drugs, such as Mytesi for HIV-related diarrhea and Gelclair for oral mucositis. Its revenue is derived from the sale of these branded prescription products and licensing agreements.Animal HealthHealthcareSecondaryThe company has a dedicated Animal Health segment that develops and markets gastrointestinal therapies for companion animals, specifically the product Canalevia-CA1 for chemotherapy-induced diarrhea in dogs.Classified using BQ-MICSCIK: 0001585608
Investment Thesis
▲ Bull case
Jaguar Health's strategic focus on late-stage crofelemer programs for ultra-rare and high-need indications positions the company to capture significant value through non-dilutive partnerships, with management highlighting transformative catalysts in MVID and SBS where no approved treatments exist, and crofelemer demonstrated a 37% reduction in parenteral support in investigator-initiated trials presented at NASPGHAN, a result that is both life-extending and disease-modifying for a patient population of 100-200 globally, creating a clear path to orphan drug designation in the U.S. and Europe and potential breakthrough or PRIME designation by end of 2026, which could accelerate regulatory approval and reimbursement access despite the small patient pool due to the severity of unmet need and lack of alternatives.
The company's cancer therapy-related diarrhea (CTD) program leverages the already FDA-approved Mytesi formulation for HIV-related diarrhea, eliminating chronic safety and manufacturing regulatory hurdles that typically derail NDAs, with plans to initiate a pivotal randomized withdrawal trial in metastatic breast cancer patients in early 2026 to support a supplemental NDA filing by end of 2026, targeting approximately 160,000 metastatic breast cancer patients in the U.S., of whom 40% discontinue life-saving targeted therapies due to diarrhea, representing a substantial commercial opportunity where crofelemer could improve both quality of life and cancer therapy outcomes by enabling treatment adherence.
On the Animal Health, Jaguar is advancing Canalevia for general diarrhea in dogs through partnership negotiations aimed at expanding the U.S. indication beyond chemotherapy-induced diarrhea, securing EU approval based on existing Jaguar studies, and maintaining U.S. availability for chemotherapy-induced diarrhea, with management indicating discussions are underway with multiple potential animal health partners to close a deal in the very near future, which would generate non-dilutive funding and validate the translational potential of crofelemer across species while reducing reliance on human drug development timelines.
Jaguar Health's strategic focus on late-stage crofelemer programs for ultra-rare and high-need indications positions the company to capture significant value through non-dilutive partnerships, with management highlighting transformative catalysts in MVID and SBS where no approved treatments exist, and crofelemer demonstrated a 37% reduction in parenteral support in investigator-initiated trials presented at NASPGHAN, a result that is both life-extending and disease-modifying for a patient population of 100-200 globally, creating a clear path to orphan drug designation in the U.S. and Europe and potential breakthrough or PRIME designation by end of 2026, which could accelerate regulatory approval and reimbursement access despite the small patient pool due to the severity of unmet need and lack of alternatives.
The company's cancer therapy-related diarrhea (CTD) program leverages the already FDA-approved Mytesi formulation for HIV-related diarrhea, eliminating chronic safety and manufacturing regulatory hurdles that typically derail NDAs, with plans to initiate a pivotal randomized withdrawal trial in metastatic breast cancer patients in early 2026 to support a supplemental NDA filing by end of 2026, targeting approximately 160,000 metastatic breast cancer patients in the U.S., of whom 40% discontinue life-saving targeted therapies due to diarrhea, representing a substantial commercial opportunity where crofelemer could improve both quality of life and cancer therapy outcomes by enabling treatment adherence.
On the Animal Health, Jaguar is advancing Canalevia for general diarrhea in dogs through partnership negotiations aimed at expanding the U.S. indication beyond chemotherapy-induced diarrhea, securing EU approval based on existing Jaguar studies, and maintaining U.S. availability for chemotherapy-induced diarrhea, with management indicating discussions are underway with multiple potential animal health partners to close a deal in the very near future, which would generate non-dilutive funding and validate the translational potential of crofelemer across species while reducing reliance on human drug development timelines.
Despite optimistic timelines, Jaguar Health provided no concrete updates on partnership progress during the Q&A, with management repeatedly referencing ongoing negotiations without disclosing timelines, terms, or counterparties for any of the three late-stage initiatives, raising concerns that the expected non-dilutive funding from business development deals may be delayed or fail to materialize, especially given the company's history of relying on such partnerships to fund development and the absence of any signed agreements or milestone payments mentioned in the transcript or recent news.
Financial performance remains stagnant and deteriorating on a year-over-year basis, with Q3 2025 net revenue of approximately $3.1 million equaling Q3 2024 levels and showing only a 4% sequential increase from Q2 2025, while Mytesi prescription volume decreased by 3.6% compared to Q3 2024, indicating persistent commercial weakness in the core HIV-related diarrhea product despite non-GAAP recurring EBITDA losses improving slightly from $9.2 million to $8.9 million, suggesting that cost-cutting is driving marginal EBITDA improvements rather than revenue growth, and the company continues to operate with substantial quarterly operating losses of approximately $7.3 million.
The regulatory pathways for both MVID/S SBS and CTD indications remain uncertain and contingent on successful trial outcomes and FDA engagement, with management acknowledging that the expedited review pathway for MVID is based on continued results from a small patient pool and the randomized withdrawal trial for CTD is not yet initiated, creating significant execution risk where failure to replicate the 37% parenteral support reduction in MVID or demonstrate efficacy in the CTD trial could delay or derail NDA filings beyond the end of 2026 timeline, leaving the company without near-term catalysts to offset its cash burn and dependence on future partnership success.
Despite optimistic timelines, Jaguar Health provided no concrete updates on partnership progress during the Q&A, with management repeatedly referencing ongoing negotiations without disclosing timelines, terms, or counterparties for any of the three late-stage initiatives, raising concerns that the expected non-dilutive funding from business development deals may be delayed or fail to materialize, especially given the company's history of relying on such partnerships to fund development and the absence of any signed agreements or milestone payments mentioned in the transcript or recent news.
Financial performance remains stagnant and deteriorating on a year-over-year basis, with Q3 2025 net revenue of approximately $3.1 million equaling Q3 2024 levels and showing only a 4% sequential increase from Q2 2025, while Mytesi prescription volume decreased by 3.6% compared to Q3 2024, indicating persistent commercial weakness in the core HIV-related diarrhea product despite non-GAAP recurring EBITDA losses improving slightly from $9.2 million to $8.9 million, suggesting that cost-cutting is driving marginal EBITDA improvements rather than revenue growth, and the company continues to operate with substantial quarterly operating losses of approximately $7.3 million.
The regulatory pathways for both MVID/S SBS and CTD indications remain uncertain and contingent on successful trial outcomes and FDA engagement, with management acknowledging that the expedited review pathway for MVID is based on continued results from a small patient pool and the randomized withdrawal trial for CTD is not yet initiated, creating significant execution risk where failure to replicate the 37% parenteral support reduction in MVID or demonstrate efficacy in the CTD trial could delay or derail NDA filings beyond the end of 2026 timeline, leaving the company without near-term catalysts to offset its cash burn and dependence on future partnership success.